The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001378314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
19/10/2026
Date registered
Help: Date registered
17/11/2026
Date last updated
Help: Date last updated
17/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/11/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
TAILORs: Time of Administration of Immunotherapy Leading to Optimal Results in patients with advanced or metastatic cancers of the lung, kidney and bladder and melanoma.
Scientific title
TAILORs: Time of Administration of Immunotherapy Leading to Optimal Results.
Registry based, randomised trial assessing the impact of treatment administration time of immunotherapy on cancer survival outcomes and on the incidence of severe adverse events in patients with advanced or metastatic NSCLC, urothelial cancer, renal cancer and melanoma
Additional trial identifiers [1] 318676 0
Nil
Universal Trial Number (UTN)
Trial acronym
TAILORs
Related trial records

Health condition
Health condition(s) studied:
Non-small cell lung cancer (NSCLC) 343885 0
Clear cell renal cell carcinoma (ccRCC) 343886 0
Urothelial carcinoma (UC) 343887 0
Melanoma 343888 0
Condition category
Condition code
Cancer 340029 340029 0 0
Lung - Non small cell
Cancer 340030 340030 0 0
Kidney
Cancer 340031 340031 0 0
Bladder
Cancer 340032 340032 0 0
Malignant melanoma

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Eligible patients will will be randomised in a 1:1 ratio to one of 2 treatment administration time periods prior to commencing a standard of care immunotherapy based regimen as first-line systemic therapy for advanced or metastatic NSCLC, ccRCC, urothelial cancer or melanoma.
Arm A will receive early treatment, with the immunotherapy component of treatment commencing before 11am.
Arm B will receive later treatment, with the immunotherapy component of treatment commencing after 12pm.

In both arms, treatment will consist of standard of care immunotherapy +/- chemotherapy or targeted therapy, as appropriate for the cancer type.
Patients will be stratified based on primary tumour type.

Treatment will be prescribed by the treating medical oncologist, and delivered in the oncology treatment area of their hospital as either as an out-patient or in-patient.

The treatment cycle length and frequency is determined by the standard of care treatment regimen prescribed. Standard cycle lengths vary between 14 and 42 days according to local institutional practice.
The time of administration of the immunotherapy component of treatment will be fixed for at least the first 3 months of therapy.

Treatment will be permanently discontinued for the following reasons:
- Progressive disease
- Unacceptable toxicity
- Investigator decision
- Patient decision
- Death

Patients who discontinue for any of the reasons listed above, with the exception of death or patient full withdrawal, will be followed up for 48 months until death, withdrawal of consent, loss to follow up or study completion, whichever comes first.
Intervention code [1] 335567 0
Treatment: Other
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 347185 0
To determine if early (prior to 11:00) versus later (after 12:00) of time-of-administration of immunotherapy impacts progression-free survival (PFS) in advanced or metastatic malignancies (NSCLC, urothelial carcinoma, clear cell renal cell carcinoma and melanoma).
Timepoint [1] 347185 0
Tumour imaging will be performed at 12 weeks +/- 7 days after the first dose of immunotherapy, then as per local standard practice thereafter.
Secondary outcome [1] 469400 0
Efficacy of early versus later time-of-administration of immunotherapy in advanced or metastatic malignancies.
Timepoint [1] 469400 0
Tumour imaging performed at 12 weeks +/- 7 days after the first dose of immunotherapy, then as per local standard practice thereafter.
Secondary outcome [2] 469830 0
Safety of early versus later time-of-administration of immunotherapy in advanced or metastatic malignancies.
Timepoint [2] 469830 0
irAEs and SAEs will be recorded from first dose of immunotherapy to 90-days after the last dose of immunotherapy.

Eligibility
Key inclusion criteria
1. Signed informed consent obtained prior to any study specific procedures and willingness to comply with study requirements.
2. Adults, aged greater than or equal to 18 years.
3. Eastern Cooperative Group (ECOG) performance status of 0 to 2.
4. Histologically or cytologically confirmed advanced or metastatic solid tumour, either:
• Non-small cell lung carcinoma (NSCLC) with documented absence of genomic alterations eligible for Pharmaceutical Benefits Scheme (PBS) subsidised targeted therapy in the first-line setting (including absence of activating epidermal growth factor receptor (EGFR) mutations, B-Raf proto-oncogene serine/threonine kinase (BRAF) V600E mutations, Mesenchymal-Epithelial Transition proto-oncogene (MET) exon 14 skipping alterations, rearranged during transfection (RET) fusion, or anaplastic lymphoma kinase (ALK) or ROS Proto-Oncogene 1 (ROS1) gene rearrangements); or
• Clear cell renal cell carcinoma (ccRCC); or
• Urothelial carcinoma (UC); or
• Melanoma
5. Eligible for an immunotherapy-based regimen (with or without chemotherapy or a tyrosine-kinase inhibitor) subsided through the PBS for first-line standard of care systemic therapy.
6. No prior anti-cancer therapy for advanced or metastatic disease.
NB: Patients with advanced or metastatic urothelial carcinoma who have not progressed following first-line platinum-based chemotherapy and are eligible to commence PBS-subsidised avelumab are permitted.
NB: Patients with locally advanced unresectable NSCLC who have received definitive chemoradiotherapy and are planned to commence maintenance durvalumab are not permitted.
7. Considered fit for this standard of care treatment by the investigator.
8. A life expectancy of greater than or equal to 12 weeks.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Prior treatment with an immune checkpoint inhibitor in any treatment setting.
2. Not suitable for a standard of care immunotherapy-based regimen, as judged by the treating clinician.
3 Patients with any of the following histology subtypes:
• Small cell neuroendocrine carcinoma
• Uveal melanoma
• Non-clear cell renal cell carcinoma
4. Current or prior use of immunosuppressive therapy within 14 days of randomisation except for inhaled or intranasal corticosteroids or systemic corticosteroids at a dose of less than or equal to 10mg/day oral prednisolone or equivalent.
5. Uncontrolled concomitant or intercurrent illness that may jeopardize the ability of the patient to undergo the procedures outlined
6 Active or symptomatic brain metastases.
7. Have a history of another primary malignancy within five years prior to randomisation except for curatively treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin or superficial transitional cell carcinoma of the bladder. Patients with a history of other malignancies are eligible if they have been disease free for at least five years after definitive primary treatment.
8. Participation in an interventional clinical trial or use of an investigational medicinal product within 28 days of randomisation.
9. Significant infection, including known chronic active hepatitis B, active hepatitis C or HIV.
10. Pregnancy, lactation, or inadequate contraception.


Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation with block sizes 2 and 4 to assign patients to arm A or arm B in a 1:1 ratio
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Assuming a 30% improvement in PFS with IO morning-administration, HR 0.70, a sample size of 284 patients will detect this difference with an 80% power.
The sample size was determined through Monte Carlo simulation with the following assumptions:
• Patients are recruited in a random pattern based on a Poisson distribution, averaging 12 per month.
• Patients are assigned to treatment arms using permuted block randomisation with block sizes 2 and 4.
• PFS times are exponentially distributed. Patients are recruited from various tumour streams,
each with a different prevalence.
• Recruitment closes when the target sample size is reached, or at 3 years, whichever is earlier.
• Patients are lost to follow-up at a constant hazard, averaging 5% per 4 years. Final data cutoff
is at 4 years.
Based on 100,000 simulations with the above assumptions, a sample size of 284 provides 80.02% power to detect a hazard ratio of 0.7 at a 5% significance level. The number of simulations is in line with FDA guidance for simulation studies.

PFS will be calculated as the time from randomisation to first disease progression or death from any cause, whichever occurs first.
Clinician assessed disease progression will be determined by local standard practice based on radiological and/or clinical factors. Determination of disease progression should be unequivocal and defined as any of the following:
- Unequivocal and clinically meaningful increase in size of known tumours, assessed by the treating clinician, guided by Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 criteria
- Appearance of one or more new lesions
- Death due to disease without prior documentation of progression
- Symptomatic deterioration not attributable to any reversible cause

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 30370 0
Mildura Base Hospital - Mildura
Recruitment hospital [2] 30372 0
Ballarat Health Services (Base Hospital) - Ballarat Central
Recruitment hospital [3] 30373 0
Latrobe Regional Hospital - Traralgon
Recruitment hospital [4] 30374 0
Goulburn Valley Health - Shepparton campus - Shepparton
Recruitment hospital [5] 30375 0
Bendigo Health Care Group - Bendigo Hospital - Bendigo
Recruitment postcode(s) [1] 46785 0
3500 - Mildura
Recruitment postcode(s) [2] 46787 0
3350 - Ballarat Central
Recruitment postcode(s) [3] 46788 0
3844 - Traralgon
Recruitment postcode(s) [4] 46789 0
3630 - Shepparton
Recruitment postcode(s) [5] 46790 0
3550 - Bendigo

Funding & Sponsors
Funding source category [1] 323244 0
Government body
Name [1] 323244 0
Department of Health, Disability and Ageing - Medical Research Future Fund (MRFF)
Country [1] 323244 0
Australia
Primary sponsor type
Hospital
Name
Grampians Health Ballarat
Address
Country
Australia
Secondary sponsor category [1] 326211 0
None
Name [1] 326211 0
Address [1] 326211 0
Country [1] 326211 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321639 0
The Royal Melbourne Hospital Human Research Ethics Committee
Ethics committee address [1] 321639 0
Ethics committee country [1] 321639 0
Australia
Date submitted for ethics approval [1] 321639 0
29/07/2026
Approval date [1] 321639 0
09/10/2026
Ethics approval number [1] 321639 0
HREC/131173/MH-2026

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 154362 0
A/Prof Wasek Faisal
Address 154362 0
Ballarat Regional Integrated Cancer Centre (BRICC), 1 Drummond Street North, Ballarat VIC 3350
Country 154362 0
Australia
Phone 154362 0
+61 3 5320 8500
Fax 154362 0
Email 154362 0
Contact person for public queries
Name 154363 0
Wasek Faisal
Address 154363 0
Ballarat Regional Integrated Cancer Centre (BRICC), 1 Drummond Street North, Ballarat VIC 3350
Country 154363 0
Australia
Phone 154363 0
+61 3 5320 8500
Fax 154363 0
Email 154363 0
Contact person for scientific queries
Name 154364 0
Wasek Faisal
Address 154364 0
Ballarat Regional Integrated Cancer Centre (BRICC), 1 Drummond Street North, Ballarat VIC 3350
Country 154364 0
Australia
Phone 154364 0
+61 3 5320 8500
Fax 154364 0
Email 154364 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Only aggregated data will be available



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.